Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.
Nat Rev Drug Discov
; 11(12): 909-22, 2012 Dec.
Article
em En
| MEDLINE
| ID: mdl-23197038
ABSTRACT
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Indústria Farmacêutica
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Descoberta de Drogas
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article